Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ZVRA

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVRA
DateTimeSourceHeadlineSymbolCompany
12/17/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024NASDAQ:ZVRAZevra Therapeutics Inc
12/06/20245:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
12/06/20245:00PMGlobeNewswire Inc.Zevra Therapeutics Announces Organizational ChangesNASDAQ:ZVRAZevra Therapeutics Inc
11/26/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
11/21/20244:51PMGlobeNewswire Inc.Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
11/14/20244:53PMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ZVRAZevra Therapeutics Inc
11/14/20241:00PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ZVRAZevra Therapeutics Inc
11/13/20244:18PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
11/12/20244:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
11/12/20244:05PMGlobeNewswire Inc.Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
11/11/20244:36PMGlobeNewswire Inc.Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
11/06/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13NASDAQ:ZVRAZevra Therapeutics Inc
10/31/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024NASDAQ:ZVRAZevra Therapeutics Inc
10/16/20244:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
10/10/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCNASDAQ:ZVRAZevra Therapeutics Inc
10/09/20249:00AMGlobeNewswire Inc.NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
09/24/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024NASDAQ:ZVRAZevra Therapeutics Inc
09/20/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
09/20/202412:08PMGlobeNewswire Inc.Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
09/06/20248:30AMGlobeNewswire Inc.Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumNASDAQ:ZVRAZevra Therapeutics Inc
08/29/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
08/13/20244:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
08/13/20244:05PMGlobeNewswire Inc.Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:ZVRAZevra Therapeutics Inc
08/13/20245:45AMIH Market NewsU.S. Futures Climb Before Inflation Data; Oil Slips on OPEC Demand CutNASDAQ:ZVRAZevra Therapeutics Inc
08/09/20245:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
08/09/20244:54PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVRAZevra Therapeutics Inc
08/09/202412:00AMGlobeNewswire Inc.Zevra Therapeutics Announces Pricing of Underwritten Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
08/08/20244:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
08/08/20244:06PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVRAZevra Therapeutics Inc
08/08/20244:01PMGlobeNewswire Inc.Zevra Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVRA

Your Recent History

Delayed Upgrade Clock